Phase I trial of intravesical Bacillus Calmette–Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette–Guérin treatment-Reference-Cited by-同舟云学术

Phase I trial of intravesical Bacillus Calmette–Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette–Guérin treatment

Published:2021-05-08 Issue:10 Volume:39 Page:3807-3813
ISSN:0724-4983
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Alanee Shaheen,Sana Sherjeel,El-Zawahry Ahmed,Peabody James,Pearce Tiffany,Adams Nicole,Deebajah Mustafa,Crabtree Jane,Delfino Kristin,McVary Kevin,Robinson Kathy,Rao Krishna

Funder

Merck

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

https://link.springer.com/content/pdf/10.1007/s00345-021-03716-3.pdf

Reference12 articles.

1. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA et al (2000) Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163(4):1124–1129

2. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR (1997) The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158(1):62–67

3. Daniels MJ, Barry E, Schoenberg M, Lamm DL, Bivalacqua TJ, Sankin A, et al (2020) Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer. Urol Oncol 38(1):5 e9–5 e16